Biotech Values

[ciotera]

Re: poor sales of first gen PIs in japan

I wouldn't judge Telaprevir sales in Japan too harshly. When comparing to the other G7 markets, one needs to discount for the super slow adoption speed in Japan (driven by general physician conservatism as well as a regulatory environment that discourages prescribing within the first year post-launch). But obviously, Japan's very old HCV population does make it more likely that patients will get warehoused for an IFN-free regimen.